RLAY — Relay Therapeutics Inc. stock price and chart

Share this page

RLAY

$16.28-5.90%

as of close, Oct 16, 2026

☾ AH $16.28 -5.90%

Relay Therapeutics Inc.Stock · HealthcareRussell 2000 0.09%Nasdaq Composite 0.008%US Stock Market 0.006%Russell 3000 0.004%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Jul 21, 2020

VolumeEEEE

20202022202320252026

10.020.030.040.050.060.0010.0M20.0M$16.28

2026-10-16

Price$16.28

MA20$18.87

MA50$14.54

Vol9.1M

What would $1,000 invested in RLAY be worth today? →

RLAY returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $16.28
YTD price return: +92.43%
YTD total return: +92.43%
Next earnings: Nov 5, 2026
Market cap: 3.6B2020-09 3.8B2026-10 3.6B-6.9% over the window
Enterprise value: 3.5B
Shares outstanding: 219.1M2019-12 4M2026-06 219.1M+5327.7% over the window
52W low: $5.95
52W high: $21.27
From 52W high: -23.46%
From 52W low: +173.61%
52W range: 67%

Volume

Rel volume: 0.71×
30D volume: 3.3M
30D $ vol: 61.4M

Fundamentals

Sales (ttm): 10.3M2020-12 82.7M2026-06 10.3M-87.5% over the window
Sales/share: $0.052020-12 $0.912026-06 $0.05-94.8% over the window
EPS (ttm): -$1.312020-12 -$5.402025-12 -$1.61-70.2% over the window
FCF (ttm): -212.2M2019-12 -74.1M2026-06 -212.2M+186.2% over the window
FCF/share: -$0.972019-12 -$18.362026-06 -$0.97-94.7% over the window
Book value/share: $4.062019-12 -$44.692026-06 $4.06-109.1% over the window
Net margin: -2763.64%2020-12 -63.4%2026-06 -2763.6%+4258.3% over the window
ROE: -32.14%2020-12 -6.9%2026-06 -32.1%+368.0% over the window
ROA: -29.57%2019-12 -19.2%2026-06 -29.6%+54.3% over the window
Current ratio: 18.272019-12 30.082026-06 18.27-39.3% over the window

Growth (CAGR, ttm) · 10Y

Sales: +23.88%2025-06-30 → 2026-06-308.4M → 10.3M (+23.9% total)+122.27%2023-06-30 → 2026-06-30942K → 10.3M (+998.7% total)-31.48%2020-12-31 → 2026-06-3082.7M → 10.3M (-87.5% total)n/a
Shares: +27.12%2025-06-30 → 2026-06-30172.4M → 219.1M (+27.1% total)+21.51%2023-06-30 → 2026-06-30122.1M → 219.1M (+79.4% total)+18.78%2021-06-30 → 2026-06-3092.7M → 219.1M (+136.4% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: -2.55%2025-06-30 → 2026-06-30$0.05 → $0.05 (-2.5% total)+82.93%2023-06-30 → 2026-06-30$0.01 → $0.05 (+512.4% total)-41.68%2020-12-31 → 2026-06-30$0.91 → $0.05 (-94.8% total)n/a
Book value/share: +5.20%2025-06-30 → 2026-06-30$3.86 → $4.06 (+5.2% total)-15.08%2023-06-30 → 2026-06-30$6.63 → $4.06 (-38.8% total)-9.45%2021-06-30 → 2026-06-30$6.67 → $4.06 (-39.1% total)n/a
Price: +150.23%2025-10-16 → 2026-10-16$6.51 → $16.28 (+150.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+32.89%2023-10-16 → 2026-10-16$6.94 → $16.28 (+134.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-13.75%2021-10-15 → 2026-10-16$34.11 → $16.28 (-52.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +150.23%2025-10-16 → 2026-10-16$6.51 → $16.28 (+150.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+32.89%2023-10-16 → 2026-10-16$6.94 → $16.28 (+134.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-13.75%2021-10-15 → 2026-10-16$34.11 → $16.28 (-52.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -12.5×2020-09 -50.892026-10 -12.47-75.5% over the window
Fwd P/E: -10.7×
P/S (ttm)Market cap ÷ TTM revenue.: 344.7×2020-12 45.452026-10 344.70+658.3% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.0×2020-09 5.372026-10 4.01-25.4% over the window
EV/Sales (ttm): 336.0×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -5.95%2020-12 -2.8%2026-06 -5.2%+86.2% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 219.1M ÷ 172.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -27.12%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-27.12%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($596.5M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -27.12%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($3.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2020-12 -0.0%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($3.6B). Same caveat as the cash buyback yield.: 0.00%2020-12 -0.0%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/S: 65th
P/B: 72nd

Bar = where today’s multiple sits in RLAY’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-5.90%

-8.95%

-13.59%

-15.95%

YTD

+92.43%

+150.08%

-52.27%

Financial statements

Open full RLAY financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

RLAY — Relay Therapeutics Inc. price, chart and key statistics